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• Otitis media affects nearly all children worldwide. Despite an 
enormous amount of research, our understanding of this 
common condition continues to be challenged.
• New pathogens involved in otitis media are still being 
identified. The importance of interactions between viral and 
bacterial infection and the role of new vaccines need to be 
clarified.
• The proposal that bacteria can become more resistant to 
therapy through biofilm formation and intracellular infection 
could have important implications for treatment.
• The most important clinical research findings have been 
summarised in systematic reviews. In developed countries, 
research supporting “watchful waiting” of otitis media with 
effusion and acute otitis media have had most impact on 
evidence-based clinical practice guidelines.
• Indigenous Australian children remain at risk of more severe 
otitis media. Research programs targeting this population 
have been well supported. Unfortunately, interventions that 
can dramatically improve outcomes have remained elusive.
• For children at high risk of otitis media, health care services 
should concentrate on accurate diagnosis, antibiotic 
treatment of suppurative infections, and scheduled follow-up 
of affected children.
• Despite the lack of recent studies, strategies to minimise 
the impact the hearing loss associated with otitis media are 
important. Improvements in education, hygiene practices, 
and living conditions are likely to reduce the incidence and 
severity of otitis media. Studies of these types of interventions 
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are needed.he
cu
tioT re is a substantial amount of research on otitis mediarrently available. Even when considering specific condi-ns, such as otitis media with effusion (OME), acute otitis
media (AOM) or chronic suppurative otitis media (CSOM), the
amount of information available can be overwhelming. This means
that it can be difficult for clinicians to keep up to date.
Advances in our understanding of the genetics, aetiology, patho-
genesis and treatment of otitis media and its sequelae have been
significant. Unfortunately, despite the large amount of research
answered. In
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Methods of literature review
To inform this article, we searched MEDLINE using PubMed from
1 January 2000 (search terms “otitis media AND ‘2000/01/
01’[PDAT] : ‘2009/04/30’[PDAT]” yielded 6271 hits). One of us
(P S M) scanned all the titles to identify important themes of recent
research. Those described in this article were agreed on by
consensus of all authors.
We also searched for the most clinically relevant articles in the
recent overseas literature (search terms “otitis media AND ‘clinical
trial’[pt] OR ‘systematic’[sb] AND ‘2000/01/01’[PDAT] : ‘2009/04/
30’[PDAT]” yielded 725 hits) and any otitis media research
conducted in Australia (search terms “otitis media AND Australia*
AND ‘2000/01/01’[PDAT] : ‘2009/04/30’[PDAT]” yielded 161
hits). All English language original research articles or systematic
reviews were eligible for inclusion. Our search identified over 50
systematic reviews and over 100 clinical trials. Around 80 publica-
tions were linked to research studies conducted in Australia.
Important research findings
At the most basic level, there have been some important develop-
ments in our understanding of the pathophysiology of otitis media.
Polymerase chain reaction (PCR) methods are now being widely
applied. The sensitivity of these methods compared with culture-
based approaches has led to an appreciation that small numbers of
bacteria and viruses (previously unrecognised) are often present in
middle ear fluid; truly sterile effusions are unusual. Although this
is interesting, the fact that PCR-positive, culture-negative bacterial
mucosal infections are milder than culture-positive infections
makes the clinical significance of PCR results uncertain.3
New pathogens such as human metapneumovirus4,5and Alloio-
coccus otitidis6-9 have been identified. The importance of interac-
tion between viruses and bacteria (and between bacterial species)
is recognised. However, translating this knowledge into better
health outcomes is not straightforward.
Several publications have reported the finding of bacterial
biofilm (an aggregate of organisms held together by an extracellu-
lar matrix) on the middle ear mucosa of children with OME and
CSOM.10,11 Modalities to break down this biofilm matrix include
physical destruction, enzymes, calcium ion inhibitors, and agents
that interfere with quorum sensing (a communication method
used by bacteria to coordinate gene expression).12 It has been
proposed that “collateral damage” from the host inflammatory
response might account for the chronicity of inflammation in
longstanding OME. The finding of bacteria intracellularly in the
mucosal lining cells of the middle ear in children with OME and
recurrent AOM (RAOM) creates another dilemma — which came
first, the biofilm or intracellular infection?13 Current research by
this group is focusing on the correlation between intracellular
bacteria found in the adenoids with those found in the middle ear
(Harvey Coates, Clinical Professor, University of Western Australia,
personal communication). The findings of significant carriage of
intracellular bacteria within the adenoids of children with RAOM
and OME could lead to further trials to assess the role of
adenoidectomy at the time of drainage of the middle ear fluid.
Clinical research studies have documented changing patterns of
antibiotic resistance and pneumococcal serotype replacement fol-
lowing the introduction of the 7-valent pneumococcal conjugater 9 • 2 November 2009 S73
SU PPLEMENTvaccine. Although the impact of this vaccine on invasive pneumo-
coccal disease has been substantial, well designed, large ran-
domised controlled trials have shown that the reduction in risk of
AOM is minimal.14 An important trial of an alternative 11-valent
pneumococcal conjugate vaccine (now 10-valent) suggested that
AOM caused by non-typeable Haemophilus influenzae may be (to
an extent) a vaccine-preventable disease.15 If the Haemophilus
protein D carrier protein is confirmed to be protective against non-
typeable H. influenzae disease, this would stimulate more work on
otitis media vaccines based on bacterial surface proteins. The role
of viral vaccines in the prevention of otitis media has been
documented for seasonal influenza infection. Other vaccines in
development (such as a respiratory syncytial virus vaccine) could
also have an impact.
A large number of randomised controlled trials examining
treatment of otitis media have been summarised in systematic
reviews and evidence-based guidelines.16 Importantly, “watchful
waiting” has emerged as an appropriate management strategy for
OME and AOM in developed countries. Trials of “wait and see”
prescribing have shown that provision of a prescription (for
antibiotic treatment if the child does not improve spontaneously)
can reduce the need for antibiotic therapy without compromising
clinical care.17,18
Individual patient data meta-analyses have provided further
important information. Although children under 2 years of age
with bilateral AOM or otorrhoea are most likely to benefit from
antibiotic treatment, subgroups of children most likely to benefit
from surgery for chronic OME have not yet been identified.19,20
Despite the ready availability of high-quality evidence, studies
suggest that there has been no reduction in active treatment
strategies used by Australian doctors.21,22
The Australian contribution
Australian research into otitis media includes:
• studies of animal models assessing potential vaccine candidates
and pathogen interactions;23,24
• microbiological assessment of specimens from the naso-
pharynx, middle ear, and ear discharge;25-27
• mathematical modelling of otitis media pathogen interactions;28
• prevalence surveys;29
• epidemiological studies of risk factors;30
• research into features of mastoiditis31,32 and cholesteatoma;33,34
• reported management of otitis media;35,36
• clinical assessment of video-otoscopy;37
• the effect of swimming pools on otitis media;38
• measurement of speech comprehension in children with a
history of otitis media;39
• the impact of CSOM on sense of smell;40
• the effect of fruit consumption;41
• the effects of surgery, including insertion of ventilation
tubes,42,43 adenoidectomy,44 and myringoplasty;45,46
• the effects of antibiotic therapy;47-49 and
• the impact of the newly introduced 7-valent conjugate
pneumococcal vaccine.50
Early onset of nasopharyngeal colonisation with Streptococcus
pneumoniae, H. influenzae, and Moraxella catarrhalis is an important
feature of severe disease in Aboriginal children.25,51 An increased
density of these bacterial pathogens is associated with more severe
disease.52 The presence of these bacteria on the hands of young
children explains why transmission rates are likely to be high.53
One of the earliest reports of Pseudomonas biofilm in otitis media
came from an Aboriginal child with CSOM.54 Similarly, two
Australian groups noted high recovery of a slow-growing aerobic
gram-positive bacterium, Alloiococcus otitidis, in 20%–60% of
middle ear effusions on PCR assay or on special culture.9,13,55 A
study of middle ear effusions in 39 ears from 25 children, using
16S ribosomal RNA sequencing of extracted DNA, showed that
35% of organisms isolated were A. otitidis.55 Further studies to
determine the pathogenicity of the organism are warranted.
The Kalgoorlie Otitis Media Research Project found the meas-
urement of otoacoustic emissions in 1–3-month-old Aboriginal
children could predict children at risk for subsequent otitis
media,56 and noted high rates of early nasopharyngeal bacteria
carriage,51 and that environmental tobacco smoke was a risk factor
in otitis media.30 A follow-up study will evaluate otitis media
screening and an awareness program regarding passive smoking
and hand hygiene.
Australian researchers have been very active in supporting
evidence-based practice for treatment of otitis media.57 Many
contribute as authors and editors of systematic reviews published
in the Cochrane Library. Efforts are made to ensure that all
resources useful in the management of otitis media among
Indigenous Australians are freely available on the Australian
Indigenous HealthInfoNet (http://www.healthinfonet.ecu.edu.au/
other-health-conditions/ear). Australian researchers also contrib-
ute to better health interventions by conducting randomised
controlled trials. Four Australian randomised controlled trials of
otitis media management have been published since the year
2000, and others are in progress (or awaiting publication). Most of
the trials (3/4) have addressed antibiotic use in Aboriginal children
(topical ciprofloxacin ear drops for CSOM47,48 and long-term
amoxycillin prophylaxis for infants).49 One trial assessed the use of
topical lignocaine for children with AOM.58 A CSOM study
contributed to a change in clinical practice, with topical cipro-
floxacin drops now approved for use in Aboriginal and Torres
Strait Islander children.47 The findings of the trials on long-term
antibiotics and local anaesthetics could also be applied clinically.
Clinical implications
It is important to recognise that only a small proportion of the
medical literature should be applied in clinical practice. Clinical
epidemiologists have estimated that approximately 2% of publica-
tions are methodologically rigorous and useful to clinicians.59
Clinicians caring for children with otitis media are most interested
in studies that assess the accuracy of diagnostic tests or the
potential health benefits of interventions. A recent Australian
review summarised the findings of systematic reviews relevant to
clinical practice.60 The key points were summarised as follows:
• pneumatic otoscopy and/or tympanometry are the only reliable
methods for detecting the presence of middle ear effusion;
• Australian Indigenous children have the highest burden of otitis
media of any children in the world;
• immediate antibiotic treatment is optional for non-Indigenous
children with AOM;
• non-Indigenous children with OME can be observed safely for
3–6 months; and
• children with CSOM need ear cleaning and topical antibiotics
until the discharge resolves.60
Overall, the results of systematic reviews of studies conducted
overseas will be applicable to Australian children. The potentialS74 MJA • Volume 191 Number 9 • 2 November 2009
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whom perforation of the tympanic membrane and subsequent
CSOM is common. Importantly, there are also important contex-
tual issues to be considered in remote communities.61 It is likely
that Australian studies would also be needed to clarify the most
appropriate health care interventions.
New initiatives
Research into otitis media in Australia has been well supported by
the National Health and Medical Research Council (NHMRC) and
the Australian Government Department of Health and Ageing.
Most research in Australia has focused on potential vaccines62 and
reducing the burden of otitis media among Indigenous chil-
dren.26,63 Studies of the pathophysiology of disease are still
underway. They include an assessment of the role of viruses in
determining tympanic membrane perforation, mathematical mod-
elling of transmission and ear state dynamics, and intensive
molecular investigation of nasopharyngeal swabs to identify the
full range of colonising pathogenic and non-pathogenic organisms.
Improvements in technology have made the assessment of genetic
risk factor studies feasible.64 Two studies examining the genetics of
RAOM are being conducted in Western Australia. One study is
looking for genetic indicators and their immunological correlates
of RAOM in children 3 years and under. The other is examining
familial history and DNA testing of 1000 children with RAOM
(and their close relatives), seeking to identify the genes associated
with the disease.
Important new randomised controlled trials in progress include:
• maternal immunisation with pneumococcal vaccine during
pregnancy;
• antibiotics for the treatment of asymptomatic bulging of the
tympanic membrane identified on screening;
• family support by Indigenous health brokers;
• enhanced family support via telephone, fax, email and mail; and
• smoking cessation strategies for parents.
Other ongoing studies include surveillance of pneumococcal
and H. influenzae carriage and presence in middle ear effusions in
the era of pneumococcal vaccination and changing antibiotic use;
and an assessment of the association between swimming pools in
remote communities and otitis media.
Surveillance of nasopharyngeal carriage organisms is comple-
mentary to routinely collected data on rates of invasive pneumo-
coccal disease, and is ongoing in the Northern Territory and WA.
This should help predict the potential impact of new vaccines.
Other potential randomised controlled trials that are yet to receive
funding include assessments of the effect of maternal immunisa-
tion with influenza vaccine, the role of combining two different
conjugate pneumococcal vaccines, and surgical interventions for
chronic OME.
To date, there is no evidence that screening for otitis media or
hearing loss due to middle ear disease is associated with substantial
health benefit (or harm).65 For Aboriginal children, the high rates of
poor outcomes provide a persuasive argument for more active
surveillance of at-risk children.66 A program of active surveillance is
currently being evaluated in the Goldfields region of WA. However,
determining whether identified children will benefit from sub-
sequent action is important. Potential interventions include medical
or surgical treatments and assistance with hearing and communica-
tion. It is likely that randomised controlled trial designs will be
needed for many of these types of questions. Improvements in
medical record management may also improve quality of care. New
medical record documentation applications, such as MMEx (Medi-
cal Message Exchange), that are being utilised in Aboriginal health
services in WA allow a patient’s medical history, audiometry results,
and video-otoscopic images to be emailed to distant experts.
Patients in Australia may also benefit from the results of more
innovative research studies. The use of non-pathogenic bacteria
and xylitol gum may have a role in treatment.67,68 New concepts of
biofilm and intracellular bacteria in middle ear disease may lead to
changes in our clinical approach (eg, use of mechanical irrigation
methods for treating CSOM) and preference for antibiotics (eg,
azithromycin or ciprofloxacin) that are concentrated intracellu-
larly. New research into surgical interventions may lead to bio-
degradable grommets, totally implantable hearing aids and tissue-
engineered tympanic membranes. Japanese investigators have
successfully performed 30 myringoplasties using tissue growth
factors and fibrin glue, with a primary healing of 73%, a further
20% with the second application and total success at the third
procedure.69 It remains to be seen whether these outpatient
procedures are appropriate interventions for the significant
number of Indigenous adults and children with CSOM.
The interface between medicine and education is critical in
dealing with otitis media and its complications. Unfortunately,
there has been little recent research addressing this issue in
Australia. Caregivers who deal directly with affected children and
their families (whether they are teachers, Aboriginal health work-
ers, community nurses, or general practitioners) must educate
families regarding the effect of hearing loss on speech, language
and education. All schools with high numbers of children with
hearing impairments should have classroom sound field systems
with wireless infrared technology. Support for training speech
pathologists, audiologists, and teachers of the deaf to work in
regional and remote Australia is needed to address a chronic
shortage of these important professionals. All these professions
should offer programs that increase the number of practising
Indigenous clinicians.
Conclusions
Research in Australia is making an important contribution to the
literature worldwide. Systematic reviews and studies of a high-risk
population (Indigenous children) have been most informative. As
“watchful waiting” becomes the preferred standard of care in
developed countries, Australian researchers are ideally placed to
determine the health benefits (and harms) of interventions for
populations with high rates of suppurative complications. Over the
next 10 years, identification of subgroups of patients most likely to
benefit from more active management will probably be the most
significant development worldwide. New therapies are unlikely to
be as important as the more appropriate application of currently
available interventions. At this point in time, Aboriginal Medical
Services should concentrate on accurate diagnosis, antibiotic treat-
ment, and scheduled follow-up of affected children. Strategies to
minimise the impact of hearing loss are equally important. Crucially,
advocates for Indigenous child health recognise that improvements
in education, hygiene practices, and living conditions are likely to
reduce the prevalence and severity of otitis media.MJA • Volume 191 Number 9 • 2 November 2009 S75
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